Interv Akut Kardiol. 2021;20(3):133-138 | DOI: 10.36290/kar.2021.031

Iopromide-paclitaxel balloon catheters in coronary interventions

Leoš Pleva
Kardiovaskulární oddělení, Interní a kardiologická klinika, FN Ostrava
Lékařská fakulta Ostravské univerzity, Ostrava

Drug-eluting balloon catheters allow local delivery into the vessel wall of an effective antiproliferative agent which reduces neointimal hyperplasia. Given its capacity to easily bind to the surface of the balloon catheter and rapidly penetrate into tissues, paclitaxel is mainly used as the active substance. The method of paclitaxel binding to the surface of the balloon catheter plays a crucial role. Iopromide is most commonly used as a carrier which increases the solubility of paclitaxel and its penetration into tissues. Iopromide-paclitaxel balloon catheters have been shown to be effective in the treatment of in-stent restenosis, particularly in bare metal stents. Another area of application could be the treatment of small coronary artery stenoses.

Keywords: iopromide-coated paclitaxel-eluting balloon catheter, in-stent restenosis, de-novo lesion.

Accepted: September 29, 2021; Prepublished online: September 29, 2021; Published: October 21, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pleva L. Iopromide-paclitaxel balloon catheters in coronary interventions. Interv Akut Kardiol. 2021;20(3):133-138. doi: 10.36290/kar.2021.031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004; 110: 810-814. Go to original source... Go to PubMed...
    2. Speck U, Scheller B, Abramjuk C, et al. Inhibition of restenosis in stented porcine coronary arteries: uptake of Paclitaxel from angiographic contrast media. Invest Radiol 2004; 39: 182-186. Go to original source... Go to PubMed...
    3. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87-165. Go to original source... Go to PubMed...
    4. Jeger RV, Eccleshall S, Ahmad WAW, et al. Drug-coated balloons for coronary artery disease third report of the international dcb consensus group. J Am Coll Cardiol Intv 2020; 13(12): 1391-1402. doi: 10.1016/j.jcin.2020.02.043. Go to original source... Go to PubMed...
    5. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated ballon catheter. N Engl J Med 2006; 355: 2113-2124. Go to original source... Go to PubMed...
    6. Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008; 97: 773-781. Go to original source... Go to PubMed...
    7. Scheller B, Clever YP, Kelsch B, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. J Am Coll Cardiol Intv 2012; 5: 323-30. Go to original source... Go to PubMed...
    8. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009; 119: 2986-2994. Go to original source... Go to PubMed...
    9. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study. EuroInterv 2015; 11: 926-34. Go to original source... Go to PubMed...
    10. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent in-stent restenosis. JACC 2014; 63: 1378-1386. Go to original source... Go to PubMed...
    11. Alfonso F, Pérez-Vizcayno MJ, del Blanco BG, et al. Long-term results of everolimus-eluting stents versus drug-eluting balloons in patients with bare-metal in-stent restenosis 3-year follow-up of the RIBS V Clinical Trial. J Am Coll Cardiol Intv 2016; 9: 1246-55. Go to original source... Go to PubMed...
    12. Pleva L, Kukla P, Kusnierova P, et al. Comparison of the efficacy of paclitaxel-eluting balloon catheters and everolimus eluting stents in the treatment of coronary in-stent restenosis. The treatment of in-stent restenosis study. Circ Cardiovasc Interv 2016; 9: e003316. Go to original source... Go to PubMed...
    13. Pleva L, Kukla P, Zapletalova J, et al. Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study. Catheter Cardiovasc Interv 2018; 00: 1-9. Go to original source... Go to PubMed...
    14. Rittger H, Brachmann J, Sinha AM, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol 2012; 59: 1377-1382. Go to original source... Go to PubMed...
    15. Rittger H, Waliszewski M, Brachmann J, et al. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty Insights From the PEPCAD-DES Study J Am Coll Cardiol Intv 2015; 8: 1695-700. Go to original source... Go to PubMed...
    16. Habara S, Iwabuchi M, Inoue N, et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J 2013; 166: 527-533. Go to original source... Go to PubMed...
    17. Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 2013; 381: 461-467. Go to original source... Go to PubMed...
    18. Xu B, Gao R, Wang J, et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drugeluting stent in-stent restenosis: results from the PEPCAD China ISR trial. J Am Coll Cardiol Intv 2014; 7: 204-211. Go to original source... Go to PubMed...
    19. Xu B, Qian J, Ge J, et al. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis. Cathet Cardiovasc Intervent 2016; 87: 624-629. Go to original source... Go to PubMed...
    20. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, et al. A prospective randomized trial of drug - eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: the RIBS IV randomized clinical trial. J Am Coll Cardiol 2015; 66: 23-33. Go to original source... Go to PubMed...
    21. Alfonso F, Pérez-Vizcayno MJ, Cuesta J, et al. 3-year clinical follow-up of the RIBS IV clinical trial: a prospective randomized study of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis in coronary arteries previously treated with drug-eluting stents. JACC Cardiovasc Interv 2018; 11(10): 981-991. Go to original source... Go to PubMed...
    22. Wong YTA, Kang DY, Lee JB, et al. Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial Am Heart J 2018; 197: 35-42. Go to original source... Go to PubMed...
    23. Baan J, Claessen BE, Dijk KB, et al. A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis: the DARE Trial. JACC Cardiovasc Interv 2018; 11(3): 275-283. Go to original source... Go to PubMed...
    24. Pleva L, Kukla P, Zapletalova J, et al. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis. BMC Cardiovasc Disor 2017; 17: 168. Go to original source... Go to PubMed...
    25. Wöhrle J, Zadura M, Möbius-Winkler S, et al. SeQuent Please World Wide Registry: Clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. JACC 2012; 60: 1733-1738. Go to original source... Go to PubMed...
    26. Stella PR, Belkacemi A, Waksman R, et al. The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. EuroInterv 2011; 7: 705-710. Go to original source... Go to PubMed...
    27. Loh JP, Pieter R. Stella PR, et al. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial. Cardiovasc Revasc Med 2014; 15: 23-28. Go to original source... Go to PubMed...
    28. Nijhoff F, Stella PR, Troost MS, et al. Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis. Clin Res Cardiol 2016; 105: 401-411. Go to original source... Go to PubMed...
    29. Assadi-Schmidt A, Mohring A, Liebsch E, et al. SeQuent Please vs. Pantera Lux drug coated balloon angioplasty in real life: Results from the Düsseldorf DCB registry. Int J Cardiol 2017; 231: 68-72. Go to original source... Go to PubMed...
    30. Chen Y, Gao L, Qin Q, et al. Comparison of 2 different drug-coated balloons in in-stent restenosis The RESTORE ISR China Randomized Trial. J Am Coll Cardiol Intv 2018; 11: 2368-77. Go to original source... Go to PubMed...
    31. Hamm CW, Dörr O, Woehrle J, et al. A multicentre, randomised controlled clinical study of drug-coated balloons for the treatment of coronary in-stent restenosis. EuroInterv 2020; 16: e328-34. Go to original source... Go to PubMed...
    32. Ali RM, Kader MAA, Ahmad WAW, et al. Treatment of coronary drug-eluting stent restenosis by a sirolimus - or paclitaxel-coated balloon. J Am Coll Cardiol Intv 2019; 12: 558-66. Go to original source... Go to PubMed...
    33. Giacoppo D, Alfonso F, Xu B, et al. Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). Eur Heart J 2019: 0; 1-14.
    34. Yerasi C, Case BC, Forrestal BJ, et al. Drug-coated balloon for de novo coronary artery disease. JACC state-of-the-art review. J Am Coll Cardiol 2020; 75: 1061-73. Go to original source... Go to PubMed...
    35. Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 2010; 96: 1291-6. Go to original source... Go to PubMed...
    36. Jeger RV, Farah A, Ohlow MA, et al. Drug-coated balloons for small coronary artery disease (BASKET SMALL 2): an open-label randomised noninferiority trial. Lancet 2018; 392: 849-56. Go to original source... Go to PubMed...
    37. Megaly M, Rofael M, Saad M, et al. Outcomes with drug-coated balloons in small-vessel coronary artery disease. Catheter Cardiovasc Interv 2019; 93: E277-86. Go to original source... Go to PubMed...
    38. Pöss, J., Jacobshagen, C., Ukena, C. et al. Hotlines and clinical trial updates presented at the German Cardiac Society Meeting 2010: FAIR-HF, CIPAMI, LIPSIA-NSTEMI, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis. Clin Res Cardiol. 2010; 99, 411-417. Go to original source... Go to PubMed...
    39. Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol 2012; 60: 2473-80. Go to original source... Go to PubMed...
    40. Tang Y, Qiao S, Su X, et al. Drug-coated balloon versus drug-eluting stent for small-vessel disease: the RESTORE SVD China randomized trial. JACC Cardiovasc Interv 2018; 11: 2381-92. Go to original source... Go to PubMed...
    41. Gobic D, Tomulic V, Lulic D, et al. Drug-coated balloon versus drug-eluting stent in primary percutaneous coronary intervention: a feasibility study. Am J Med Sci 2017; 354: 553-60. Go to original source... Go to PubMed...
    42. Clever YP, Cremers B, Krauss B, et al. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smoothmuscle cells. EuroInterv 2011; 7: K32-42. Go to original source... Go to PubMed...
    43. Clever YP, Peters D, Calisse J, et al. Novel sirolimus-coated balloon catheter in vivo evaluation in a porcine coronary model. Circ Cardiovasc Interv 2016; 9: e003543. Go to original source... Go to PubMed...
    44. Lemos PA, Farooq V, Takimura CK, et al. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroInterv 2013; 9: 148-156. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.